ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.215,39
0,28%
S&P 500
5.477,90
0,16%
Dow Jones
39.127,80
0,00%
Euro vs US Dollar
1,07013
0,20%
Bitcoin
61.157,38
0,57%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. iTeos Therapeutics Inc (ITOS)

  7. iTeos Therapeutics Inc (ITOS) News

ITOS

iTeos Therapeutics (ITOS)

iTeos Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ITOS
DatumZeitQuelleÜberschriftSymbolFirma
17/06/202415h00GlobeNewswire Inc.iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerNASDAQ:ITOSiTeos Therapeutics Inc
14/06/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
14/06/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
14/06/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
13/06/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITOSiTeos Therapeutics Inc
13/05/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITOSiTeos Therapeutics Inc
10/05/202422h35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414h26GlobeNewswire Inc.iTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414h24GlobeNewswire Inc.iTeos Therapeutics Announces $120 Million Registered Direct OfferingNASDAQ:ITOSiTeos Therapeutics Inc
07/04/202422h30GlobeNewswire Inc.iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024NASDAQ:ITOSiTeos Therapeutics Inc
09/03/202402h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
09/03/202402h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
09/03/202401h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
09/03/202401h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
08/03/202402h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
08/03/202402h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h09Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h01GlobeNewswire Inc.iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of DirectorsNASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413h00GlobeNewswire Inc.iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
05/03/202422h30GlobeNewswire Inc.iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024NASDAQ:ITOSiTeos Therapeutics Inc
01/03/202413h00GlobeNewswire Inc.iTeos to Participate in Upcoming Investor ConferencesNASDAQ:ITOSiTeos Therapeutics Inc
10/01/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITOSiTeos Therapeutics Inc
08/01/202413h00GlobeNewswire Inc.iTeos Announces 2024 Strategic Priorities and Anticipated MilestonesNASDAQ:ITOSiTeos Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.iTeos to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ITOSiTeos Therapeutics Inc
08/12/202302h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
08/12/202302h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
08/12/202302h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
08/12/202302h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ITOS

Kürzlich von Ihnen besucht

USOTC
BASFY
BASF (QX)
TG
LHA
Deutsche Lufthansa
NYSE
KO
Coca Cola
FX
EURUSD
Euro vs US Dollar
CCOM
SILVER
SILVER
COIN
ETHUSD
Ethereum
NYSE
MRK
Merck
CCOM
US30
US 30
TG
BAYN
Bayer
TG
RHM
Rheinmetall
AMEX
XLE
Energy Select Sector SPDR
AMEX
XLF
Financial Select Sector
NYSE
JPM
JP Morgan Chase
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLV
Health Care Select Sector
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten